HHS IG subpoenas Procrit documents
Johnson & Johnson is responding to a subpoena from HHS' Office of Inspector General for documents related to the sales and marketing of the anemia treatment Procrit (epoetin alfa). The company said it received the subpoena Sept. 30 and is cooperating in responding to it. Procrit marketing is also under scrutiny by New York Attorney General Eliot Spitzer (1"The Pink Sheet" DAILY, Aug. 5, 2004)...
You may also be interested in...
Procrit, Risperdal and four other leading J&J pharmaceutical brands are the subject of a document request from New York Attorney General Eliot Spitzer. J&J is already facing two federal investigations into marketing practices.
Beiersdorf and former owner Bayer are on the verge of settling a proposed class action in California’s Northern District challenging “mineral-based” claims on Coppertone sunscreens that also contain chemical UV filters. However, the parties will have to try again with their proposed terms.
The MHRA is in listening mode as it gathers feedback to shape the UKCA marking for medical devices. See what Phil Brown, regulatory director of the Association of British HealthTech Industries, said about it here.